Last10K.com

Innate Pharma Sa (IPHA) SEC Filing 6-K Foreign Issuer report for the period ending Wednesday, May 6, 2020

Innate Pharma Sa

CIK: 1598599 Ticker: IPHA

View differences made from one to another to evaluate Innate Pharma Sa's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 6-K Foreign Issuer Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Innate Pharma Sa.

Continue

Assess how Innate Pharma Sa's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Innate Pharma Sa's Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Material Contracts, Statements, Certifications & more

Innate Pharma Sa provided additional information to their SEC Filing as exhibits

Ticker: IPHA
CIK: 1598599
Form Type: 6-K Foreign Issuer Report
Accession Number: 0001171843-20-003351
Submitted to the SEC: Wed May 06 2020 6:30:14 AM EST
Accepted by the SEC: Wed May 06 2020
Period: Wednesday, May 6, 2020
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/ipha/0001171843-20-003351.htm